CONTINUING MEDICAL EDUCATION
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 12.5 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

WHO SHOULD ATTEND
This educational activity is intended for oncologists, radiation therapists, thoracic surgeons, pulmonologists and other physicians in active clinical practice interested and/or involved in the management of patients with thoracic cancer.

 

OBJECTIVES
After successful completion of this continuing medical education activity, participants should be able to:

• Describe the epidemiology of lung cancer and emerging screening techniques

• Discuss the methodology of smoking cessation

• Recommend the most appropriate management strategies for non-small cell lung cancer (NSCLC), including selecting patients fortherapy and predicting benefit

• Compare and contrast invasive versus non- invasive (MRI, CT, PET) procedures in the staging of lung cancer

• Recommend the most appropriate management strategies for small cell lung cancer

• Identify controversies in management of locally advanced NSCLC

• Analyze available and emerging treatment options in advanced NSCLC

• Translate the results of recent clinical trials in lung cancer and incorporate them into clinical practice

• Outline management strategies for esophageal cancer

• Outline management strategies for mesothelioma

• Describe the emerging role of targeted therapies in the treatment of thoracic malignancies and optimal strategies for patient selection

• Discuss surgical issues and controversies related to treatment of thoracic cancers

 

Jeffrey D. Bradley, MD Siteman Cancer Center St. Louis, Missouri Barbara A. Burtness, MD Fox Chase Cancer Center Philadelphia, Pennsylvania Roger B. Cohen, MD Fox Chase Cancer Center Philadelphia, Pennsylvania Walter J. Curran, Jr., MD, FACR Emory University Atlanta, Georgia Carolyn M. Dresler, MD, MPA University of Arkansas for Medical Sciences Little Rock, Arkansas John R. Eckardt, MD The Center for Cancer Care and Research St. Louis, Missouri Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Baltimore, Maryland David S. Ettinger, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland Ramaswamy Govindan, MD Washington University in St. Louis School of Medicine St. Louis, Missouri

Nasser H. Hanna, MD Indiana University Indianapolis, Indiana Roy S. Herbst, MD, PhD M. D. Anderson Cancer Center Houston, Texas Vera Hirsh, MD McGill University Montreal, Quebec, Canada James R. Jett, MD Mayo Clinic Rochester, Minnesota Mark G. Kris, MD Memorial Sloan-Kettering Cancer Center New York, New York Rodney J. Landreneau, MD University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Corey J. Langer, MD, FACP University of Pennsylvania Philadelphia, Pennsylvania John J. Nemunaitis, MD Mary Crowley Medical Research Center Dallas, Texas Harvey I. Pass, MD New York University New York, New York

Roman Perez-Soler, MD Albert Einstein Cancer Center New York, New York Helen J. Ross, MD Mayo Clinic Scottsdale, Arizona Walter J. Scott, MD, FACS Fox Chase Cancer Center Philadelphia, Pennsylvania Gerard A. Silvestri, MD, MS Medical University of South Carolina Charleston, South Carolina George R. Simon, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida Louis Souhami, MD McGill University Faculty of Medicine Montreal, Quebec, Canada Eric Vallieres, MD, FRCSC Swedish Cancer Institute Seattle, Washington Henry Wagner, MD Pennsylvania State Cancer Institute Hershey, Pennsylvania

Friday, November 21, 2008

Session I: Introductory lectures

8:10 am
Welcome Corey J. Langer, MD

8:20 am
Lung cancer – New millennial perspective on epidemiology, risk factors, and genetics
Mark G. Kris, MD

8:45 am
Saving lives pre-emptively: How to facilitate smoking cessation
Carolyn M. Dresler, MD, MPA

9:10 am
Lung cancer screening in 2008: Truth and consequences?
James R. Jett, MD

9:35 am
Panel discussion

9:55 am
Break

Session II: Non-small cell lung cancer (NSCLC)

10:15 am
Case presentation Anatomic resection – Can we do more with less?
No – Rodney J. Landreneau, MD
Yes – Walter J. Scott, MD, FACS

11:00 am
Cost-effective staging in NSCLC
Gerard A. Silvestri, MD, MS

11:20 am
Is there a role for adjuvant radiotherapy in resected NSCLC?
Louis Souhami, MD

11:40 am
Panel discussion

12:00 pm
Lunch

Session III: Locally advanced NSCLC

1:00 pm
Identifying the optimal approach for patients with locally advanced, unresectable NSCLC
Medical oncologist perspective - Corey J. Langer, MD
Radiation oncologist perspective - Walter J. Curran Jr., MD, FACR

1:45 pm
Management of locally advanced, potentially resectable NSCLC: Is surgery worth the morbidity?
Harvey I. Pass, MD

2:05 pm
Image-guided radiation therapy: Does dose escalation of RT in the face of standard chemotherapy enhance outcome?
Jeffrey D. Bradley, MD

2:25 pm
Targeting VEGF and EGFR in the treatment of locally advanced NSCLC
Ramaswamy Govindan, MD

2:45 pm
Panel discussion

3:05 pm
Break

Session IV: Advanced NSCLC

3:25 pm
First-line treatment for advanced NSCLC: Has the time for molecular determination finally arrived?
Helen J. Ross, MD

3:45 pm
Optimizing patient selection with respect to targeted agents
Roman Perez-Soler, MD

4:05 pm
Second- and third-line treatment options in NSCLC: Is there a “state of the art?”
Nasser H. Hanna, MD

4:25 pm
Panel discussion

4:45 pm
Adjournment

 

Saturday, November 22, 2008

8:00 am
Welcome to day two
Corey J. Langer, MD

8:05 am
Special Topics in Thoracic Oncology -- Esophageal cancer: What’s new; What’s not?
Barbara A Burtness, MD

Session V: SCLC

8:25 am
Case presentation SCLC: Will we ever alter the standard paradigm in limited disease?
David S. Ettinger, MD

9:10 am
Prophylactic cranial irradiation (PCI): Why does this strategy make such a difference in SCLC?
Henry Wagner, MD

9:30 am
First- and second-line therapy in SCLC: Developing new agents in the face of therapeutic stagnation
John Eckardt, MD

9:50 am
Panel discussion

10:10 am
Break

Session VI: Targeted therapies and immunomodulation

10:30 am
Bevacizumab: Has the clinical perspective been altered by AVAiL?
Vera Hirsh, MD

10:50 am
Beyond bevacizumab: Future role of angiogenesis inhibition and vascular disruption in NSCLC
Martin J. Edelman, MD

11:10 am
Beyond VEGF and angiogenesis inhibitors: New targets and agents that warrant attention in NSCLC
Roger B Cohen, MD

11:30 am
Will cetuximab eclipse the oral EGFR small molecule inhibitors? Does “FLEX” offer us more flexibility?
Roy S. Herbst, MD, PhD

11:50 am
Will vaccines have a role in early stage and locally advanced NSCLC?
John J. Nemunaitis, MD

12:10 pm
Panel discussion

12:30 pm
Lunch

Session VII: Surgical controversies in thoracic oncology

1:35 pm
RFA vs wedge resection vs SBRT: How do we address the ever shrinking SPN (solitary pulmonary nodule)?
Walter J. Scott, MD, FACS

1:55 pm
Mediastinal lymph nodes: Does extent of dissection influence outcome?
Eric Vallieres, MD, FRCSC

2:15 pm
Special Topics in Thoracic Oncology -- Mesothelioma: Has survival plateaued after pemetrexed?
George R. Simon, MD

2:35 pm
Panel discussion

2:55 pm
Chairman summary and take home points
Corey J. Langer, MD

3:00 pm
Adjourn

REGISTRATION FEES

Discounted . . . . . . . . . . . . . . . . . . . .$225.00
Payment received by September 18, 2008

Regular . . . . . . . . . . . . . . . . . . . .$325.00
Payment received by November 13, 2008

Full/Onsite . . . . . . . . . . . . . . . . . .$425.00
Payment received after November 13, 2008

Group discount (physicians only)* . . -$50.00
*Cannot be combined with any other discounts

Nurses/Residents/Students . . . . . . . $99.00
*Proof of eligibility must accompany registration

To Register: You may register online by November 13, 2008 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

Group Discounts: Each one of multiple registrants from the same institute or practice receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician.

Payment: To pre-register, registration and payment must be received no later than November 13, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Include the full name of the attendee and the name of the conference: Perspectives in Thoracic Oncology A040.01. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 13, 2008. The amount of registration fees remitted, less a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 13, 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

New York Marriott East Side
525 Lexington Avenue
New York, New York 10017
Tel: + 1 (212) 755 4000
Fax: +1 (212) 751 3440
www.marriott.com/hotels/travel/nycea-new-york-marriott-east-side/

When visiting the Big Apple, there`s no better place to stay than the New York Marriott East Side. Having just completed a $24 million guest room renovation, this hotel in Midtown Manhattan, NY is a treasure of rare distinction among other East Side New York hotels. The hotel`s 629 guestrooms and 17 suites feature luxurious bed linens, 32 inch plasma-screen HDTVs and ample business amenities. Guests will delight in the newly renovated health club and upgraded concierge lounge with outdoor terraces. Enjoy close proximity to Midtown Manhattan`s best attractions including Rockefeller Center, Broadway theaters and shopping on Madison Avenue.

For the convenience of attendees, a limited number of rooms have been reserved until October 31, 2008 at a discounted rate of $429 single/double occupancy, plus tax, currently at 13.375%. This rate is not guaranteed outside the conference dates or after October 31, 2008. Additional nights will be subject to rate and room availability.

To reserve your room please contact the New York Marriott East Side reservations department at +1 (212) 755 4000. Callers must identify themselves as being with the Perspectives in Thoracic Oncology group. Reservation requests received after October 31, 008 may not be guaranteed the group rate.

 

CHAIR
Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

 

LETTER FROM THE CHAIR
Dear Colleague,
It is with great pleasure and enthusiasm that I invite you to attend the 13th Annual Perspectives in Thoracic Oncology. This fall’s conference, to be held November 21-22, 2008 at the New York Marriott East Side, promises to be our most exciting meeting yet! Over the past thirteen years, this meeting has become a premier source for updates in thoracic oncology; it provides attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options. There is great need among thoracic oncology clinicians and researchers to obtain the latest information on the complex pathology and treatment of lung cancer. The field is constantly evolving and there are many issues in disease biology, management, and research that are intensely debated among those involved in these fields. This conference will be a great place to interact with your colleagues and learn from internationally renowned faculty, as well as the diverse mix of oncologists, surgeons, and pulmonologists. I hope you will be able to join me for this exciting two day meeting; I look forward to welcoming you to New York as the fall brings its beauty to this international city.

Sincerely,
Corey J. Langer, MD, FACP
Chair

 

ORGANIZER
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

 

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

©2008 Imedex^®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

CORPORATE SUPPORT
The following companies have provided an unrestricted educational grant in support of this conference:

Platinum Genentech BioOncology & OSI Oncology   Gold   Bronze Corporate

 

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.